List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2312616/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>FAM19A4/miR124-2</i> Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. Clinical Infectious Diseases, 2023, 76, e827-e834.	2.9	4
2	Association of preoperative cone biopsy with recurrences after radical hysterectomy. Archives of Gynecology and Obstetrics, 2022, 305, 215-222.	0.8	9
3	Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. Gynecologic Oncology, 2022, 164, 68-75.	0.6	12
4	Causation and causal inference in obstetrics-gynecology. American Journal of Obstetrics and Gynecology, 2022, 226, 12-23.	0.7	2
5	Clinical Differences between Invasive Lobular Breast Cancer and Invasive Carcinoma of No Special Type in the German Mammography-Screening-Program. Women and Health, 2022, 62, 144-156.	0.4	3
6	Exome sequencing identifies RASSF1 and KLK3 germline variants in an Iranian multiple-case breast cancer family. European Journal of Medical Genetics, 2022, 65, 104425.	0.7	1
7	OUP accepted manuscript. Human Molecular Genetics, 2022, , .	1.4	1
8	Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses, 2022, 14, 893.	1.5	1
9	Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol. BMJ Open, 2022, 12, e061740.	0.8	1
10	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
11	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
12	Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. European Journal of Cancer, 2021, 143, 88-100.	1.3	27
13	Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines. Scientific Reports, 2021, 11, 1250.	1.6	6
14	CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 15.	0.7	5
15	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
16	German evidence and consensusâ€based (S3) guideline: Vaccination recommendations for the prevention of HPVâ€associated lesions. JDDG - Journal of the German Society of Dermatology, 2021, 19, 479-494.	0.4	8
17	Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study. Annals of Surgical Oncology, 2021, 28, 6696-6704.	0.7	3
18	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. Gynecologic Oncology, 2021, 161, 442-448.	0.6	4

#	Article	IF	CITATIONS
19	Classification of highâ€grade cervical intraepithelial neoplasia by p16 ^{ink4a} , Kiâ€67, <scp>HPV E4</scp> and <i><scp>FAM19A4</scp>/<scp>miR124</scp>â€2</i> methylation status demonstrates considerable heterogeneity with potential consequences for management. International Journal of Cancer, 2021, 149, 707-716.	2.3	26
20	Association of genomic variants at <scp><i>PAX8</i></scp> and <scp><i>PBX2</i></scp> with cervical cancer risk. International Journal of Cancer, 2021, 149, 893-900.	2.3	7
21	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.0	6
22	Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance. Cancers, 2021, 13, 3309.	1.7	4
23	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	1.8	18
24	Challenges and Controversies in the Surgical Treatment of Cervical Cancer: Open Radical Hysterectomy versus Minimally Invasive Radical Hysterectomy. Journal of Clinical Medicine, 2021, 10, 3761.	1.0	5
25	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	2.8	116
26	NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44. Biomedicines, 2021, 9, 1339.	1.4	18
27	Performance of a six-methylation-marker assay on self-collected cervical samples – A feasibility study. Journal of Virological Methods, 2021, 295, 114219.	1.0	8
28	CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection. International Journal of Environmental Research and Public Health, 2021, 18, 10388.	1.2	13
29	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 2021, 385, 2123-2131.	13.9	144
30	First Prospective Cross-Sectional Study on the Impact of Immigration Background and Education in Early Detection of Breast Cancer. Breast Care, 2021, 16, 516-522.	0.8	1
31	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
32	Reproductive capacity and recurrence of disease after surgery for moderate and severe endometriosis – a retrospective single center analysis. BMC Women's Health, 2020, 20, 144.	0.8	5
33	Sentinel lymph node biopsy in vulvar cancer: status, level of knowledge, and counseling in outpatient setting. Archives of Gynecology and Obstetrics, 2020, 302, 1001-1007.	0.8	0
34	Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers, 2020, 12, 2407.	1.7	32
35	Spinal Emergency Surgery During Pregnancy: Contemporary Strategies and Outcome. World Neurosurgery, 2020, 139, e421-e427.	0.7	4
36	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265

#	Article	IF	CITATIONS
37	Radical hysterectomy for early cervical cancer: what shall we do after the LACC trial?. Archives of Gynecology and Obstetrics, 2020, 302, 289-292.	0.8	7
38	Germline HOXB13 mutations p.C84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
39	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. International Journal of Cancer, 2020, 147, 2458-2468.	2.3	12
40	Recommendations Related to Genetic Testing for Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 188.	3.8	0
41	Intracranial emergencies during pregnancy requiring urgent neurosurgical treatment. Clinical Neurology and Neurosurgery, 2020, 195, 105905.	0.6	9
42	Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. International Journal of Gynecological Cancer, 2020, 30, 920-926.	1.2	3
43	Evaluation of treatment patterns and prognosis in correlation with age in patients with vulvar cancer: A subset analysis of the AGO-CaRE-1 study Journal of Clinical Oncology, 2020, 38, 6090-6090.	0.8	Ο
44	Germline variation of Ribonuclease H2 genes in ovarian cancer patients. Journal of Ovarian Research, 2020, 13, 146.	1.3	1
45	Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1221-1228.	0.8	2
46	Peritoneal contamination with <scp>ICG</scp> â€stained cervical secretion as surrogate for potential cervical cancer tumor cell dissemination: A proofâ€ofâ€principle study for laparoscopic hysterectomy. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1398-1403.	1.3	27
47	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
48	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
49	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
50	Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. Gynecologic Oncology, 2019, 154, 565-570.	0.6	16
51	A randomized trial comparing limited-excision conisation to Large Loop Excision of the Transformation Zone (LLETZ) in cervical dysplasia patients. Journal of Gynecologic Oncology, 2019, 30, e42.	1.0	10
52	Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. EBioMedicine, 2019, 43, 253-260.	2.7	37
53	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
54	Prevention of Cervical Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 148-159.	0.8	19

#	Article	IF	CITATIONS
55	Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 660.	1.8	70
56	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
57	Should we really abandon inguinal lymphadenectomy in the treatment of vulvar cancer?. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 399-399.	1.3	1
58	The influence of obesity on tumor recurrence in vulvar cancer patients Journal of Clinical Oncology, 2019, 37, e17130-e17130.	0.8	2
59	Peri- and postoperative management and outcomes of morbidly obese patients (BMI > 40Âkg/m2) with gynaecological disease. Archives of Gynecology and Obstetrics, 2018, 297, 1221-1233.	0.8	4
60	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
61	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	1.3	62
62	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetiumâ€99mâ€nanocolloid. Lasers in Surgery and Medicine, 2018, 50, 994-1001.	1.1	16
63	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
64	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
65	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
66	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
67	LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study Journal of Clinical Oncology, 2018, 36, 5575-5575.	0.8	4
68	Prospective cross-sectional-study on influence of immigration background and education on breast cancer survival in a real-world setting Journal of Clinical Oncology, 2018, 36, e18650-e18650.	0.8	0
69	Postoperative anatomic and qualityâ€ofâ€life outcomes after vaginal sacrocolporectopexy for vaginal vault prolapse. International Journal of Gynecology and Obstetrics, 2017, 137, 86-91.	1.0	2
70	Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer. Breast Cancer Research and Treatment, 2017, 162, 31-37.	1.1	5
71	Application of sentinel lymph node dissection in gynecological cancers: results of a survey among German hospitals. Archives of Gynecology and Obstetrics, 2017, 295, 713-720.	0.8	10
72	Sensitization of immune cells following hexylaminolevulinate photodynamic therapy of cervical intraepithelial neoplasia. Photodiagnosis and Photodynamic Therapy, 2017, 17, 82-86.	1.3	16

#	Article	IF	CITATIONS
73	Photodynamic diagnosis with 5â€aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study. Lasers in Surgery and Medicine, 2017, 49, 169-176.	1.1	23
74	Ultrasound versus Clinical Examination to Estimate Fetal Weight at Term. Geburtshilfe Und Frauenheilkunde, 2017, 77, 276-283.	0.8	14
75	Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. Annals of Surgical Oncology, 2017, 24, 1314-1321.	0.7	30
76	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
77	Association between intraabdominal pressure during gynaecologic laparoscopy and postoperative pain. Archives of Gynecology and Obstetrics, 2017, 295, 1191-1199.	0.8	9
78	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	0.8	28
79	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
80	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
81	Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy. Human Gene Therapy, 2017, 28, 886-896.	1.4	65
82	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	2.9	16
83	The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias. Geburtshilfe Und Frauenheilkunde, 2017, 77, 887-893.	0.8	10
84	Analysis of a RECQL splicing mutation, c.1667_1667+3delAGTA, in breast cancer patients and controls from Central Europe. Familial Cancer, 2017, 16, 181-186.	0.9	20
85	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	1.1	67
86	Maternal anxiety and its correlation with pain experience during chorion villus sampling and amniocentesis. Journal of Pain Research, 2017, Volume 10, 591-600.	0.8	11
87	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 2017, 8, 50930-50940.	0.8	43
88	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	0.8	7
89	Guideline adherence and clinical outcome in vulnerable and healthy breast cancer patients: Results of a prospective cross-sectional study in Germany Journal of Clinical Oncology, 2017, 35, e18132-e18132.	0.8	0
90	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71

#	Article	IF	CITATIONS
91	SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment. International Journal of Oncology, 2016, 49, 2453-2463.	1.4	15
92	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
93	Rare ATAD5 missense variants in breast and ovarian cancer patients. Cancer Letters, 2016, 376, 173-177.	3.2	21
94	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
95	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	9.4	77
96	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
97	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	1.1	64
98	Gestational diabetes mellitus: an evaluation of gynecologists' knowledge of guidelines and counseling behavior. Archives of Gynecology and Obstetrics, 2016, 294, 1209-1217.	0.8	4
99	Epidemiology and Early Detection of Cervical Cancer. Oncology Research and Treatment, 2016, 39, 501-506.	0.8	51
100	Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft GynĤologische Onkologie CaRE-1 multicenter study. European Journal of Cancer, 2016, 69, 180-188.	1.3	64
101	Excellent analytical and clinical performance of a dry selfâ€sampling device for human papillomavirus detection in an urban Chinese referral population. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1839-1845.	0.6	14
102	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	0.8	152
103	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	2.9	39
104	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	1.6	62
105	<i>PPM1D</i> Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. Journal of the National Cancer Institute, 2016, 108, djv347.	3.0	43
106	Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. Strahlentherapie Und Onkologie, 2016, 192, 8-16.	1.0	33
107	The paradigm shift in cervical cancer screening in Germany. Archives of Gynecology and Obstetrics, 2016, 293, 3-4.	0.8	6
108	HPV testing in the context of post-treatment follow up (test of cure). Journal of Clinical Virology, 2016, 76, S56-S61.	1.6	43

#	Article	IF	CITATIONS
109	Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia. Archives of Gynecology and Obstetrics, 2016, 293, 415-419.	0.8	44
110	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
111	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	0.8	29
112	The Benefit of Baseline Staging–Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage. Anticancer Research, 2016, 36, 4909-4914.	0.5	1
113	Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study Journal of Clinical Oncology, 2016, 34, 5595-5595.	0.8	1
114	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	1.6	35
115	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
116	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
117	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
118	Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. Expert Opinion on Investigational Drugs, 2015, 24, 273-281.	1.9	30
119	A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. American Journal of Obstetrics and Gynecology, 2015, 212, 465.e1-465.e7.	0.7	38
120	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
121	Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Archives of Gynecology and Obstetrics, 2015, 291, 623-629.	0.8	34
122	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
123	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
124	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
125	Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics, 2015, 134, 231-245.	1.8	34
126	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63

#	Article	IF	CITATIONS
127	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
128	Radiofrequency endometrial ablation for the treatment of heavy menstrual bleeding among women at high surgical risk. International Journal of Gynecology and Obstetrics, 2015, 131, 123-128.	1.0	7
129	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
130	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	1.6	25
131	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	311
132	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	1.4	50
133	Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pNO-status. Oncotarget, 2015, 6, 23015-23025.	0.8	15
134	c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations. Oncotarget, 2015, 6, 31640-31658.	0.8	18
135	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
136	Mutation Analysis of the ERCC4/FANCQ Gene in Hereditary Breast Cancer. PLoS ONE, 2014, 9, e85334.	1.1	16
137	Interference of Ca2+ with the proliferation of SCCOHT-1 and ovarian adenocarcinoma cells. International Journal of Oncology, 2014, 45, 1151-1158.	1.4	3
138	Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with lowâ€grade cervical intraepithelial neoplasia. Lasers in Surgery and Medicine, 2014, 46, 456-461.	1.1	27
139	Dermoglandular Rotation Flaps for Breast-Conserving Therapy: Aesthetic Results, Patient Satisfaction, and Morbidity in Comparison to Standard Segmentectomy. International Journal of Breast Cancer, 2014, 2014, 1-9.	0.6	6
140	Detection of E6-AP as a potential therapeutic target in cervical specimen of HPV-infected women. Archives of Gynecology and Obstetrics, 2014, 289, 1281-1286.	0.8	3
141	Eradication of cervical cancer: the beginning of the end. Archives of Gynecology and Obstetrics, 2014, 289, 477-478.	0.8	1
142	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncology, The, 2014, 15, 172-183.	5.1	508
143	Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study Journal of Clinical Oncology, 2014, 32, 5562-5562.	0.8	0
144	Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO CARE-1 multicenter study Journal of Clinical Oncology, 2014, 32, 5608-5608.	0.8	0

#	Article	IF	CITATIONS
145	The FNTB-609G>C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnib Journal of Clinical Oncology, 2014, 32, e16534-e16534.	0.8	0
146	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
147	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
148	Letter to the Editor: K. Gemzell-Danielsson et al. Emergency contraception — mechanisms of action. Contraception 87 (2013) 300–308. Contraception, 2013, 88, 581.	0.8	1
149	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
150	Outcome parameters in node-negative vulvar cancer: A subset analysis of the AGO Care 1 study Journal of Clinical Oncology, 2013, 31, 5531-5531.	0.8	0
151	Evaluation of a New Multiplex Real-Time Polymerase Chain Reaction Assay for the Detection of Human Papillomavirus Infections in a Referral Population. International Journal of Gynecological Cancer, 2012, 22, 1050-1056.	1.2	11
152	Photodynamic therapy of cervical intraepithelial neoplasia 1–3 and human papilloma virus (HPV) infection with methylaminolevulinate and hexaminolevulinate—A doubleâ€blind, doseâ€finding study. Lasers in Surgery and Medicine, 2012, 44, 468-474.	1.1	33
153	Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study Journal of Clinical Oncology, 2012, 30, 5007-5007.	0.8	5
154	Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening. Journal of Clinical Microbiology, 2011, 49, 1721-1729.	1.8	66
155	The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction after Previous Drug Extravasation. Annals of Pharmacotherapy, 2011, 45, 277-277.	0.9	4
156	Quality of life and satisfaction after breast cancer operation. Archives of Gynecology and Obstetrics, 2010, 282, 75-82.	0.8	78
157	Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. Zeitschrift Fur Gesundheitswissenschaften, 2009, 17, 77-86.	0.8	17
158	Fluorescence diagnosis and photodynamic therapy for lower genital tract diseases – A review. Medical Laser Application: International Journal for Laser Treatment and Research, 2009, 24, 10-17.	0.4	12
159	Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study. BMC Infectious Diseases, 2008, 8, 76.	1.3	87
160	Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. Lasers in Surgery and Medicine, 2008, 40, 611-615.	1.1	71
161	Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. American Journal of Obstetrics and Gynecology, 2008, 198, 300.e1-300.e7.	0.7	33
162	Invited comments. Photodiagnosis and Photodynamic Therapy, 2007, 4, 94.	1.3	0

#	Article	IF	CITATIONS
163	Lymph node metastasis detection of ovarian cancer by porphyrin fluorescence photodetection: case report. Lasers in Medical Science, 2007, 22, 131-135.	1.0	16
164	Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecologic Oncology, 2006, 100, 271-275.	0.6	161
165	Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia. Gynecologic Oncology, 2006, 100, 276-282.	0.6	65
166	Evaluation of <i>FAM19A4/miR124â€2</i> methylation performance in the management of <scp>CIN3</scp> diagnosed pregnant women. International Journal of Cancer, 0, , .	2.3	4